Can the TLR-4-Mediated Signaling Pathway Be “A Key Inflammatory Promoter for Sporadic TAA”?

Table 4

Systemic plasma mediator’s levels “AASSP” from patients and controls.

Systemic mediators examined	Patients; (𝑁=161)	Controls; (𝑁=128)	𝑃 values*
IL-6 (pg/mL)	13.69±2.1	5.1±1.9	<0.0001
TNF-𝛼 (pg/mL)	16.34±1.2	8.1±2.4	<0.0001
CRP (mg/L)	16.86±2.2	5.6±1.3	<0.0001
MMP-2 (ng/mL)	57.5±2.8	13.54±1.24	<0.0001
MMP-9 (ng/mL)	59.8±2.5	12.7±1.6	<0.0001
Systemic mediators examined	Patients with high responder genotype; (𝑁=46)	Patients with other genotypes; (𝑁=115)	𝑃 values*
IL-6 (pg/mL)	17.66±2.1	9.1±0.9	<0.001
TNF-𝛼 (pg/mL)	16.78±1.2	10.1±2.2	<0.01
CRP (mg/L)	20.13±1.7	12.1±0.5	0.01
MMP-2 (ng/mL)	61.8±3.8	26.54±1.6	<0.0001
MMP-9 (ng/mL)	59.7±3.7	21.7±2.6	<0.0001
Systemic mediators examined	Patients with high responder genotype; (𝑁=46)	Controls with high responder genotype; (𝑁=10)	𝑃 values*
IL-6 (pg/mL)	17.66±2.1	8.66±2.1	<0.0001
TNF-𝛼 (pg/mL)	16.78±1.2	10.78±1.2	<0.01
CRP (mg/L)	20.13±1.7	6.13±1.7	<0.0001
MMP-2 (ng/mL)	61.8±3.8	18.8±3.9	<0.0001
MMP-9 (ng/mL)	59.7±3.7	12.7±2.7	<0.0001

∗By unpaired 𝑡-test with Welch correction.